Compounds of formula (I):

##STR00001##

wherein Het, R.sub.3, R.sub.4, R.sub.5, R.sub.7, R.sub.8, R.sub.9, T, p, p′, q, and q′ are as defined in the description.

Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.

Compounds of formula (I):

##STR00001##

wherein Het, R.sub.3, R.sub.4, R.sub.5, R.sub.7, R.sub.8, R.sub.9, T, p, p′, q, and q′ are as defined in the description.

Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.

The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent

The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent

To provide an OCT3 activity inhibitor having a different basic skeleton than that of conventional OCT3 activity inhibitors. This inhibitor of organic cation transporter 3 (OCT3) contains, as an active component, an imidazo[1,2-a]pyridine derivative, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.

To provide an OCT3 activity inhibitor having a different basic skeleton than that of conventional OCT3 activity inhibitors. This inhibitor of organic cation transporter 3 (OCT3) contains, as an active component, an imidazo[1,2-a]pyridine derivative, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.

The present invention discloses compounds according to Formula I:

##STR00001##

Wherein R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, and Cy are as defined herein.

The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.

The present invention discloses compounds according to Formula I:

##STR00001##

Wherein R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, and Cy are as defined herein.

The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.

The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.